Academic research could be strengthened by thinking more and doing less.
November 8, 2004|
Scientists frustrated with the lack of progress toward a useful malaria vaccine may have edged a step closer to that goal with the announcement by a public-private partnership that it has created a promising candidate. GlaxoSmithKline's RTS,S/AS02A is a fusion of immunogenic components of the circumsporozoite protein with hepatitis B surface antigen, plus a proprietary adjuvant. The compound achieved a 58% efficacy against severe disease in 1- to 5-year-old children in a Phase IIb trial in Mozam